CDK4 and breast cancer: However, (a) expression of aeTSAs (e.g., from the MAGE family) can be enhanced by hypomethylating agents, and (b) one family of hypomethylating drugs (CDK4/6 inhibitors) is currently used as the first line of treatment in HR+ breast cancer.